Open Payments

Monument Health Rapid City Hospital

Type
Teaching hospital
Where
RAPID CITY, SD
Medicare CCN
430077
Received
$657,742 in 95 records, 2024 ($39,952 general, $617,789 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2024General payment41$39,952
2024Research payment54$617,789

By company

CompanyRecordsAmountYears
Amgen Inc.4$261,1902024
Eli Lilly and Company9$180,9612024
CSL Behring3$55,7202024
AstraZeneca Pharmaceuticals LP4$42,4162024
AstraZeneca UK Limited1$16,7452024
PFIZER INC.12$16,7002024
Medtronic, Inc.5$14,6532024
Alnylam Pharmaceuticals Inc.4$11,1922024
Zimmer Biomet Holdings, Inc.4$8,9882024
Sterilmed, Inc.1$8,2002024
ZOLL Respicardia, Inc.5$6,3602024
Boston Scientific Corporation8$5,0362024
Linde Gas & Equipment Inc.15$4,9502024
AngioDynamics, Inc.1$4,8002024
Novo Nordisk Inc3$3,0002024
Boehringer Ingelheim Pharmaceuticals, Inc.3$2,9972024
Novo Nordisk AS1$2,3282024
MicroVention, Inc.1$2,0002024
E.R. Squibb & Sons, L.L.C.1$1,0002024
Tandem Diabetes Care, Inc.1$1,0002024
Lilly USA, LLC1$1,0002024
Insulet Corporation1$1,0002024
Abbott Laboratories1$1,0002024
Biosense Webster, Inc.1$1,0002024
Merck Sharp & Dohme LLC1$1,0002024
Novartis Pharmaceuticals Corporation1$1,0002024
Stryker Corporation1$9732024
Gilead Sciences, Inc.1$5002024
Medline Industries LP1$282024

By nature of payment

NatureRecordsAmount
Research payment54$617,789
Space rental or facility fees (teaching hospital only)30$19,450
Compensation for services other than consulting, including serving as faculty or as a speaker at a v4$11,200
Long term medical supply or device loan2$5,773
Grant4$3,500
Debt forgiveness1$28

Records

DateCompanyAmountNatureFormProductStudyYear
2024-12-31Sterilmed, Inc.$8,200Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-12-31AngioDynamics, Inc.$4,800Long term medical supply or device loanIn-kind items and servicesVenaCure 1470 Pro Device, ET2024
2024-12-31Stryker Corporation$973Long term medical supply or device loanIn-kind items and servicesALTRIX Device, PATIENT HANDLING - PH2024
2024-12-31Medline Industries LP$28Debt forgivenessCash or cash equivalent2024
2024-12-12Medtronic, Inc.$375Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-12-12Medtronic, Inc.$375Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-12-11Medtronic, Inc.$13,403Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-12-06Alnylam Pharmaceuticals Inc.$1,942Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2024
2024-11-25Abbott Laboratories$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentFREESTYLE LIBRE 3 Device, Diabetes Care2024
2024-11-12Novo Nordisk Inc$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-11-12Boston Scientific Corporation$66Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIELEGANCE2024
2024-10-24Boston Scientific Corporation$2,500GrantIn-kind items and services Device, General - Therapies_PI2024
2024-10-24Boston Scientific Corporation$333GrantIn-kind items and services Device, General - Therapies_EP2024
2024-10-24Boston Scientific Corporation$333GrantIn-kind items and services Device, General - Therapies_EP2024
2024-10-24Boston Scientific Corporation$333GrantIn-kind items and services Device, General - Therapies_EP2024
2024-10-22Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-10-18ZOLL Respicardia, Inc.$3,832Research paymentCash or cash equivalentremede System Device, RespiratoryZOLL Respicardia, Inc. Registry Study2024
2024-10-17Merck Sharp & Dohme LLC$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentVERQUVO Drug, CARDIOVASCULAR2024
2024-10-17Novartis Pharmaceuticals Corporation$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentLEQVIO Drug, Cardiology/Vascular Diseases2024
2024-10-16Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-10-11Biosense Webster, Inc.$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2024
2024-10-08Novo Nordisk Inc$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-10-08Boston Scientific Corporation$268Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIELEGANCE2024
2024-10-04Alnylam Pharmaceuticals Inc.$1,000Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2024
2024-10-01PFIZER INC.$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2024
2024-09-30Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-09-27Boehringer Ingelheim Pharmaceuticals, Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-09-27Boehringer Ingelheim Pharmaceuticals, Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-09-27Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-09-19Tandem Diabetes Care, Inc.$1,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt:slim X2 Insulin Pump with Control-IQ Device, Endocrinology2024
2024-09-17AstraZeneca Pharmaceuticals LP$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentBRILINTA Drug, Cardiovascular and Metabolism2024
2024-09-05E.R. Squibb & Sons, L.L.C.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-09-03Eli Lilly and Company$126,413Research paymentCash or cash equivalentA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2024
2024-08-21PFIZER INC.$10,000Research paymentCash or cash equivalentTUKYSA Drug, OncologyTHE COMPASSHER2 TRIALS COMPREHENSIVE USE OF PATHOLOGIC RESPONSE ASSESSMENT TO OPTIMIZE THERAPY IN HER2POSITIVE BREAST CA2024
2024-08-19AstraZeneca Pharmaceuticals LP$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentWAINUA Drug, Cardiovascular and Metabolism2024
2024-08-15Zimmer Biomet Holdings, Inc.$1,584Research paymentCash or cash equivalentPersona Device, KneesPersona Ti-Nidium Personalized Total Knee System2024
2024-08-15Lilly USA, LLC$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-08-08Novo Nordisk Inc$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-08-07Insulet Corporation$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentOmnipod Device, Insulin Pump2024
2024-07-31AstraZeneca Pharmaceuticals LP$40,066Research paymentCash or cash equivalentA Phase III, Randomised, Double-blind Study to Evaluate the Effect of Balcinrenone/Dapagliflozin, Compared with Dapaglif2024
2024-07-15ZOLL Respicardia, Inc.$1,046Research paymentCash or cash equivalentremede System Device, RespiratoryZOLL Respicardia, Inc. Registry Study2024
2024-06-28CSL Behring$53,970Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-06-27MicroVention, Inc.$2,000Research paymentCash or cash equivalentWEB ANEURYSM EMBOLIZATION SYSTEM Device, NEUROLOGICAL PRODUCTEVALUATION OF THE ROADSAVER STENT USED IN CONJUNCTION WITH THE NANOPARASOL EMBOLIC PROTECTION SYSTEM FOR CAROTID ARTERY 2024
2024-06-25ZOLL Respicardia, Inc.$500Research paymentCash or cash equivalentremede System Device, RespiratoryZOLL Respicardia, Inc. Registry Study2024
2024-06-18Boston Scientific Corporation$202Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_PIELEGANCE2024
2024-06-14Alnylam Pharmaceuticals Inc.$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentAMVUTTRA Drug, Genetic Disease2024
2024-06-05Alnylam Pharmaceuticals Inc.$7,250Research paymentCash or cash equivalentZilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by St2024
2024-05-30Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-05-28Eli Lilly and Company$6,347Research paymentIn-kind items and servicesA PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION 2024
2024-05-25Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-05-02Gilead Sciences, Inc.$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2024
2024-05-02AstraZeneca Pharmaceuticals LP$350Research paymentCash or cash equivalentFARXIGA Drug, Cardiovascular and MetabolismDapagliflozin in Acute Decompensated Heart Failure2024
2024-04-20Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-04-20Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-04-19Amgen Inc.$91,455Research paymentCash or cash equivalentOCEANa-Outcomes P3 CV2024
2024-04-19Amgen Inc.$33,649Research paymentCash or cash equivalentRepatha Biological, Cardiology20170625_VESALIUS - CV2024
2024-04-19Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-04-15ZOLL Respicardia, Inc.$689Research paymentCash or cash equivalentremede System Device, RespiratoryZOLL Respicardia, Inc. Registry Study2024
2024-04-11Zimmer Biomet Holdings, Inc.$4,500Research paymentCash or cash equivalentPersona Device, KneesPersona Ti-Nidium Personalized Total Knee System2024
2024-04-11Zimmer Biomet Holdings, Inc.$1,320Research paymentCash or cash equivalentPersona Device, KneesPersona Ti-Nidium Personalized Total Knee System2024
2024-04-05Eli Lilly and Company$19Research paymentIn-kind items and servicesA STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O2024
2024-04-03Boehringer Ingelheim Pharmaceuticals, Inc.$997Research paymentCash or cash equivalentPhase II dose finding/PoCC in CKD2024
2024-04-03Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-03-29Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-03-22Eli Lilly and Company$1,988Research paymentCash or cash equivalentA RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS2024
2024-03-21Zimmer Biomet Holdings, Inc.$1,584Research paymentCash or cash equivalentPersona Device, KneesPersona Ti-Nidium Personalized Total Knee System2024
2024-03-19Medtronic, Inc.$250Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-03-19Medtronic, Inc.$250Research paymentCash or cash equivalentCOREVALVE EVOLUT R Device, Transcatheter Valve SystemsEXPAND II2024
2024-03-15CSL Behring$1,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-15CSL Behring$750Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2024
2024-03-11Boston Scientific Corporation$1,000Research paymentCash or cash equivalentGeneral - Brady Device, General - Brady_CRMAPPRAISE ATP2024
2024-02-16Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-02-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$600Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-15PFIZER INC.$500Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI2024
2024-02-13Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-02-12Eli Lilly and Company$2,750Research paymentCash or cash equivalentA STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND O2024
2024-02-05Eli Lilly and Company$14,683Research paymentCash or cash equivalentA RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PL2024
2024-01-30Eli Lilly and Company$20,851Research paymentCash or cash equivalentTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2024
2024-01-25Eli Lilly and Company$2,940Research paymentIn-kind items and servicesTHE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SU2024
2024-01-24Novo Nordisk AS$2,328Research paymentCash or cash equivalentRybelsus Drug, DiabetesNN9924-44372024
2024-01-24Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-01-17Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2024
2024-01-12AstraZeneca UK Limited$16,745Research paymentCash or cash equivalentA Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MED2024
2024-01-12ZOLL Respicardia, Inc.$292Research paymentCash or cash equivalentremede System Device, RespiratoryZOLL Respicardia, Inc. Registry Study2024
2024-01-08Amgen Inc.$118,227Research paymentIn-kind items and servicesRepatha Biological, Cardiology20170625_VESALIUS - CV2024
2024-01-08Amgen Inc.$17,858Research paymentIn-kind items and servicesOCEANa-Outcomes P3 CV2024
2024-01-02Eli Lilly and Company$4,970Research paymentCash or cash equivalentA RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS2024

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Pennington CountyRapid City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Rapid City, SD, county Pennington County, SD, state South Dakota; placed by its city name.

MeasurePlace (city or town)
Rapid City, SD
County
Pennington County, SD
State
South Dakota
Population B0100377,946113,512907,428
Population, 2020 census P174,703109,222886,667
Median age B0100239.140.138.0
Under 18 B0100122.0%22.0%24.2%
65 and over B0100120.7%20.1%18.0%
Households B1100132,36846,370365,544
Foreign born B050022.6%2.5%4.0%
Median household income B19013$70,870$74,517$75,081
Median family income B19113$91,802$92,479$96,562
Per capita income B19301$42,204$42,302$40,550
Poverty rate B1700112.5%11.2%11.9%
Unemployment rate B230252.6%3.2%2.9%
Civilian labor force B2302539,45257,369475,223
Mean commute (minutes) B0801317.519.417.8
Bachelor's degree or higher B1500337.0%34.6%31.9%
Housing units B2500135,57751,681408,584
Owner-occupied B2500362.9%69.3%68.6%
Renters B2500337.1%30.7%31.4%
Median home value B25077$299,400$302,200$257,400
Median gross rent B25064$1,109$1,120$946
White, not Hispanic B0300276.3%77.8%79.8%
Black B030021.2%1.1%2.1%
Hispanic or Latino B030026.1%5.7%4.8%
Asian B030021.3%1.2%1.4%
American Indian and Alaska Native B030027.1%6.0%7.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Rapid City, SD.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.